{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:45Z","timestamp":1740148965465,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","funder":[{"name":"Article processing charges and the open access charge for this NMA were funded by Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12325-016-0305-x","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T12:52:41Z","timestamp":1456491161000},"page":"519-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Xieer","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankush","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhajit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"305_CR1","unstructured":"WHO fact sheet on Hepatitis B. March 2015 [cited 2015, 5 May]; http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ ."},{"key":"305_CR2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.4254\/wjh.v7.i8.1030","volume":"7","author":"L Koumbi","year":"2015","unstructured":"Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol. 2015;7:1030\u201340.","journal-title":"World J Hepatol."},{"key":"305_CR3","unstructured":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 Mar. Publications of the World Health Organization are available on the WHO website ( http:\/\/www.who.int )."},{"key":"305_CR4","doi-asserted-by":"crossref","first-page":"e98865","DOI":"10.1371\/journal.pone.0098865","volume":"9","author":"W Ke","year":"2014","unstructured":"Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014;9:e98865.","journal-title":"PLoS One"},{"key":"305_CR5","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","volume":"35","author":"YS Hsu","year":"2002","unstructured":"Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAG seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522\u20137.","journal-title":"Hepatology"},{"key":"305_CR6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","volume":"3","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009;3:425\u201333.","journal-title":"Hepatol Int."},{"key":"305_CR7","doi-asserted-by":"crossref","first-page":"e54773","DOI":"10.1371\/journal.pone.0054773","volume":"8","author":"X Feng","year":"2013","unstructured":"Feng X, Yan L, Lu J, et al. Effects of nucleoside analogue on patients with chronic hepatitis b-associated liver failure: meta-analysis. PLoS One. 2013;8:e54773.","journal-title":"PLoS One"},{"key":"305_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/phar.1188","volume":"33","author":"A Wiens","year":"2013","unstructured":"Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144\u201351.","journal-title":"Pharmacotherapy"},{"key":"305_CR9","doi-asserted-by":"crossref","first-page":"e7862","DOI":"10.5812\/hepatmon.7862","volume":"13","author":"J Liang","year":"2013","unstructured":"Liang J, Jiang MJ, Deng X, Zhou XX. Efficacy and safety of telbivudine compared to entecavir among HBeAg+ chronic hepatitis B patients: a meta-analysis study. Hepat Mon. 2013;13:e7862.","journal-title":"Hepat Mon."},{"key":"305_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MAJ.0b013e318286878d","volume":"347","author":"H Liu","year":"2014","unstructured":"Liu H, Wang X, Wan G, Yang Z, Zeng H. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. Am J Med Sci. 2014;347:131\u20138.","journal-title":"Am J Med Sci"},{"key":"305_CR11","first-page":"297","volume":"2","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Kang S, Fang W, Wu X, Liang W. Network meta-analysis on prophylactic regimens against recurrent hepatitis B virus infection after liver transplantation. Hepatobiliary Surg Nutr. 2013;2:297\u2013303.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"305_CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades AE, Ioaniddis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17:279\u2013301.","journal-title":"Stat Methods Med Res"},{"key":"305_CR13","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http:\/\/www.cochrane-handbook.org ."},{"key":"305_CR14","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [Online]. http:\/\/www.nice.org.uk\/article\/pmg9\/chapter\/foreword . Accessed 19 Feb 2015."},{"key":"305_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"305_CR16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429\u201337.","journal-title":"Value Health"},{"key":"305_CR17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607\u201317.","journal-title":"Med Decis Making"},{"key":"305_CR18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","volume":"11","author":"DK Wong","year":"2006","unstructured":"Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antiviral Ther. 2006;11:909\u201316.","journal-title":"Antiviral Ther."},{"key":"305_CR19","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576\u201388.","journal-title":"N Engl J Med"},{"key":"305_CR20","first-page":"680","volume":"59","author":"YD Wang","year":"2012","unstructured":"Wang YD, Zhao CY, Wang W, et al. Improved efficacy by individualized combination therapy with Peg IFN-\u03b1 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology. 2012;59:680\u20136.","journal-title":"Hepatogastroenterology"},{"key":"305_CR21","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","volume":"20","author":"M Sunbul","year":"2014","unstructured":"Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20:5427\u201334.","journal-title":"World J Gastroenterol"},{"key":"305_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123\u20139.","journal-title":"Lancet"},{"key":"305_CR23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/hep.26885","volume":"59","author":"J Sun","year":"2014","unstructured":"Sun J, Xie Q, Tan D, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59:1283\u201392.","journal-title":"Hepatology"},{"key":"305_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"issue":"3","key":"305_CR25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.21758","volume":"46","author":"CK Hui","year":"2007","unstructured":"Hui CK, Leung N, Shek TW, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46(3):690\u20138.","journal-title":"Hepatology"},{"key":"305_CR26","doi-asserted-by":"crossref","first-page":"e54279","DOI":"10.1371\/journal.pone.0054279","volume":"8","author":"TKP Piratvisuth","year":"2013","unstructured":"Piratvisuth TKP, Komolmit P, Tanwandee T, et al. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279.","journal-title":"PLoS One"},{"key":"305_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","volume":"51","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11\u201320.","journal-title":"J Hepatol"},{"key":"305_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"C Chen","year":"2006","unstructured":"Chen C, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"305_CR29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","volume":"347","author":"HI Yang","year":"2002","unstructured":"Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168\u201374.","journal-title":"N Engl J Med"},{"key":"305_CR30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.22419","volume":"48","author":"A Evans","year":"2008","unstructured":"Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology. 2008;48:759\u201369.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"305_CR31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12392","volume":"34","author":"M Buti","year":"2014","unstructured":"Buti M. HBeAg-positive chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogs? Liver Int. 2014;34(Suppl 1):108\u201311.","journal-title":"Liver Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0305-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T10:07:50Z","timestamp":1654423670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0305-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0305-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2016,2,26]]}}}